CN112601513B - 治疗眼部疾病的药物 - Google Patents

治疗眼部疾病的药物 Download PDF

Info

Publication number
CN112601513B
CN112601513B CN201980037118.2A CN201980037118A CN112601513B CN 112601513 B CN112601513 B CN 112601513B CN 201980037118 A CN201980037118 A CN 201980037118A CN 112601513 B CN112601513 B CN 112601513B
Authority
CN
China
Prior art keywords
cycloalkyl
halo
alkyl
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980037118.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112601513A (zh
Inventor
苏里亚·坎塔·德
G·斯里达尔·普拉萨德
马歇尔·克拉克·彼得曼
伯纳德·科林斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxair Pharmaceutical Co
Original Assignee
Praxair Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxair Pharmaceutical Co filed Critical Praxair Pharmaceutical Co
Publication of CN112601513A publication Critical patent/CN112601513A/zh
Application granted granted Critical
Publication of CN112601513B publication Critical patent/CN112601513B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980037118.2A 2018-04-05 2019-04-05 治疗眼部疾病的药物 Active CN112601513B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862653249P 2018-04-05 2018-04-05
US62/653,249 2018-04-05
US201862694729P 2018-07-06 2018-07-06
US62/694,729 2018-07-06
PCT/US2019/026112 WO2019195761A2 (en) 2018-04-05 2019-04-05 Pharmacological agents for treating ocular diseases

Publications (2)

Publication Number Publication Date
CN112601513A CN112601513A (zh) 2021-04-02
CN112601513B true CN112601513B (zh) 2023-12-22

Family

ID=68101528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037118.2A Active CN112601513B (zh) 2018-04-05 2019-04-05 治疗眼部疾病的药物

Country Status (6)

Country Link
US (1) US11872236B2 (cg-RX-API-DMAC7.html)
JP (1) JP7532259B2 (cg-RX-API-DMAC7.html)
CN (1) CN112601513B (cg-RX-API-DMAC7.html)
BR (1) BR112020020351A2 (cg-RX-API-DMAC7.html)
MX (1) MX2020010502A (cg-RX-API-DMAC7.html)
WO (1) WO2019195761A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113692276B (zh) * 2019-02-19 2026-02-27 加利福尼亚大学董事会 Nurr1受体调节剂
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
US20220403229A1 (en) * 2019-10-28 2022-12-22 Kebotix, Inc. Electronic control of transmittance of visible and near-infrared radiation
WO2022098847A1 (en) * 2020-11-04 2022-05-12 Corino Therapeutics, Inc. Tolcapone analogs and methods of use
WO2022104383A1 (en) * 2020-11-13 2022-05-19 Plex Pharmaceuticals, Inc. Pharmacological agents for treating conditions of the eye
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
WO2023278604A1 (en) * 2021-06-29 2023-01-05 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
GB202204798D0 (en) 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone
WO2024123100A1 (ko) * 2022-12-09 2024-06-13 경희대학교 산학협력단 신규 아밀로이드-베타 응집체 분해제와 이를 이용한 뇌 표적화 약물 전달 시스템

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476875A (en) * 1986-03-11 1995-12-19 Hoffman-La Roche Inc. Catechol derivatives
CN1188755A (zh) * 1997-01-22 1998-07-29 弗·哈夫曼-拉罗切有限公司 二苯酮衍生物的制备方法
WO2014147464A2 (en) * 2013-03-20 2014-09-25 Ra Chem Pharma Limited Novel process for the preparation of tolcapone
CN106163548A (zh) * 2014-02-08 2016-11-23 健泰科生物技术公司 治疗阿尔茨海默氏病的方法
CN107206009A (zh) * 2014-08-22 2017-09-26 广州康睿生物医药科技股份有限公司 用于治疗视觉障碍的组合物和方法
WO2022104383A1 (en) * 2020-11-13 2022-05-19 Plex Pharmaceuticals, Inc. Pharmacological agents for treating conditions of the eye
WO2023278464A1 (en) * 2021-06-28 2023-01-05 Plex Pharmaceuticals, Inc. Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
JPH1036257A (ja) * 1996-05-22 1998-02-10 Kikkoman Corp メイラード反応阻害剤
JP2000256259A (ja) 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011047412A1 (en) * 2009-10-22 2011-04-28 The Heart Research Institute Ltd Tyrosine and l-dopa for reducing l-dopa incorporation into proteins
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
US20160317474A1 (en) * 2013-12-18 2016-11-03 Emory University Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476875A (en) * 1986-03-11 1995-12-19 Hoffman-La Roche Inc. Catechol derivatives
CN1188755A (zh) * 1997-01-22 1998-07-29 弗·哈夫曼-拉罗切有限公司 二苯酮衍生物的制备方法
WO2014147464A2 (en) * 2013-03-20 2014-09-25 Ra Chem Pharma Limited Novel process for the preparation of tolcapone
CN106163548A (zh) * 2014-02-08 2016-11-23 健泰科生物技术公司 治疗阿尔茨海默氏病的方法
CN107206009A (zh) * 2014-08-22 2017-09-26 广州康睿生物医药科技股份有限公司 用于治疗视觉障碍的组合物和方法
WO2022104383A1 (en) * 2020-11-13 2022-05-19 Plex Pharmaceuticals, Inc. Pharmacological agents for treating conditions of the eye
WO2023278464A1 (en) * 2021-06-28 2023-01-05 Plex Pharmaceuticals, Inc. Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Administration of antioxidant compounds affects the lens chaperone activity and prevents the onset of cataracts;Yosuke Nakazawa等;《Biomed Pharmacother》;第95卷;137-143 *
Pharmacological restoration of transparency in cataract;L. Makley等;《Acta Ophthalmologica》;20161031;第94卷(第S256期);摘要 *
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity;Ricardo Sant’Anna等;《NATURE COMMUNICATIONS》;20160223;第1-13页 *
Ricardo Sant’Anna等.Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.《NATURE COMMUNICATIONS》.2016,第1-13页. *
国家医药管理局科技教育司组织编写.成酯及成酰胺修饰.《药物化学》.中国医药科技出版社,1996,(第1版),第209页. *

Also Published As

Publication number Publication date
MX2020010502A (es) 2021-03-25
JP2021532059A (ja) 2021-11-25
BR112020020351A2 (pt) 2021-01-12
CN112601513A (zh) 2021-04-02
US20210154213A1 (en) 2021-05-27
WO2019195761A2 (en) 2019-10-10
JP7532259B2 (ja) 2024-08-13
US11872236B2 (en) 2024-01-16
EP3773438A2 (en) 2021-02-17
WO2019195761A3 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP7532259B2 (ja) 眼疾患治療薬剤
RU2470635C2 (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
JP2020050676A (ja) 抗菌性治療薬及び予防薬
ES2982308T3 (es) Péptido novedoso y composición farmacéutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmacéutico activo
JP2008247898A (ja) トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
SG10202110144TA (en) Compositions and methods for inhibiting arginase activity
JP2016528174A (ja) 治療的送達用のシクロデキストリンベースのポリマー
JP2022511371A (ja) Ｖａｐ－１の阻害剤
US20260022144A1 (en) Analgesic polypeptide
CN113811527A (zh) 双（双吖丙啶）衍生物作为光交联剂治疗角膜扩张性疾病
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
CA3202073A1 (en) Pharmacological agents for treating conditions of the eye
TW201726146A (zh) 用於預防及治療眼疼痛之氨基膦衍生物
HK40050888A (en) Pharmacological agents for treating ocular diseases
TWI590827B (zh) 以組合透明質酸及黃素腺嘌呤二核苷酸為特徵的角膜上皮細胞死亡抑制劑
JP2011225605A (ja) 点眼剤
TW201318628A (zh) 含有黃素腺嘌呤二核苷酸或其塩為有效成分之角膜上皮細胞死亡抑制劑
KR20200074179A (ko) Ret9 및 vegfr2 억제제
WO2023143575A1 (zh) 一种m-胆碱受体激动剂化合物及其制备方法和用途
CN121265611A (zh) Prc2抑制剂的新用途
BR112017025122B1 (pt) Uso de nintedanib para tratar pterígio
NZ785093A (en) Methods of treating ocular conditions
HK1193349B (en) Inhibitor for corneal epithelial cell death, inhibitor characterized by combining hyaluronic acid and flavin adenine dinucleotide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050888

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant